Case study

Measuring the Patient Health Impact of AL Amyloidosis: Capturing Heterogeneous Patient Experiences with the SF-36v2® Health Survey (SF-36v2)

In 2014, the patient experience with immunoglobulin light chain (AL) amyloidosis was not well documented in literature, and there were no existing PRO measures validated for use in studies of patients who have AL amyloidosis. In a free case study, discover how QualityMetric’s SF-36v2 health survey helped a pharmaceutical company identify critical measurement concepts for this rare disease and capture the wide variety of patient experiences, as well as their impact on other domains of patient lives.

Download the Case Study Now

THIS CASE STUDY WILL DISCUSS:

Background info and data on AL amyloidosis in the U.S. population
How PRO instruments can capture patient experiences and their impacts
The results of recent studies on patients living with AL amyloidosis

A novel approach to determining the patient health impact of AL amyloidosis, the SF-36v2 health survey measures a range of symptoms, experiences and patient health outcomes. This case study discusses how QualityMetric conducted in-depth interviews with clinicians, other experts and patients, as well as an online observational study, providing much-needed granularity into the consequences that AL amyloidosis has on patient lives.